The use of cefotaxime for the treatment of common infections: in vitro, pharmacokinetic and clinical considerations.
The use of the broad-spectrum cephalosporin, cefotaxime, in internal medicine is well-established, particularly in the treatment of moderately severe to severe community- and hospital-acquired infections. It is particularly useful for infections of the lower respiratory tract, urinary and biliary systems, skin and soft tissue, and in serious conditions, such as meningitis, particularly in pediatric patients. Knowledge of the pharmacokinetic and pharmacodynamic properties of cefotaxime supports the view that low dose (1-2 g), low frequency (12-hourly) dosage regimens are applicable to many mild-to-moderately severe infections, including community-acquired pneumonia, caused by susceptible organisms.
Wilson
W R
WR
Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55905, USA.
Bouza
E
E
Lode
H
H
Mouton
Y
Y
D000293:Adolescent; D000328:Adult; D002439:Cefotaxime / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002511:Cephalosporins / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000378:metabolism*; D003428:Cross Infection / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged
D002511:Cephalosporins; D002439:Cefotaxime